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ABSTRACT
Purpose: Investigating risk factors for amniotic fluid embolism (AFE)-induced fatality.
Methods: A systematic review of cases of AFE available on PubMed, Scielo, Scopus and AJOL
databases that occurred from 1990 to 2015 was carried out. After careful reading of titles,
abstracts and full texts, case reports of AFE were reviewed. Risk factors for AFE were considered
as independent variables in logistic regression models. The first model was built on the whole
data pool. The second model was built on typical cases of AFE, according to the classical triad of
symptoms (heart, lungs, coagulopathy). The dependent variable was fatality in both models.
Results: 177 cases of AFE were assessed in the first model, while 121 typical cases of AFE were
assessed in the second model. Among typical cases of AFE, only oxytocin infusion during labour
increases the likelihood of death (odds ratio 2.890, 95% confidence interval 1.166–7.164,
p¼ 0.022). No risk factors for fatality were found in the whole data pool.
Conclusions: Further research on national registries should focus on the behaviour of oxytocin
infusion during labour in AFE cases.
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Introduction
Amniotic fluid embolism (AFE) is a catastrophic and
uncommon complication of pregnancy [1,2].
Diagnostic criteria for defining AFE has been newly
published by Clark et al. [3], for avoiding misdiagnoses
of AFE and confusion about outcomes and manage-
ment of such a rare disease. By assessing data sources
from many countries, Knight et al. [4] extrapolated
that maternal age greater than 35 years, placenta pre-
via and placenta abruptio are risk factors for AFE, and
also that a true association could be suspected
between AFE and mode of delivery (caesarean section
is more likely to be associated with AFE cases onset-
ting afterbirth). Due to the rarity of AFE and the differ-
ent characteristics of the data sources, no clear
associations were found by Knight et al. [4] between
presumptive risk factors for AFE and fatality. More
recently, Fitzpatrick et al. [5] reported an increase in
odds ratios for AFE associated with age (equal to or
greater than 35), multiple pregnancy, induction of
labour (any method) and placenta previa. Again,
Fitzpatrick et al. [5] did not find a significant associ-
ation between any of those risk factors and fatality,
which seems less likely if immediate intervention was
provided [5].
By widely reviewing case reports of AFE in litera-
ture, we aim to test the hypothesis that, among the
risk factors for AFE reported from recent population-
based reviews [4,5], there are some factors related to
fatality.
Materials and methods
On 20 January 2016, we performed a systematic
review of the literature by introducing “amniotic” AND
“fluid” AND “embolism” as keywords in the PubMed,
Scielo, AJOL (African Journal Online) and Scopus
search engines. The time frame of the search was lim-
ited from 1990 to present, without language limitation.
The systematic review was the first step of a meta-ana-
lysis (registered in the PROSPERO database n 34104)
carried out for investigating which kind of intervention
improves AFE outcome [6].
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The phases of the systematic review and studies
selection were widely reported elsewhere [6]. By care-
fully checking the references and after discarding
duplicates and inappropriate papers, we were able to
built a data pool on AFE cases. From this data pool,
we collected information about patient outcome
(death or survival) and about several characteristics of
patients and birth. The independent variables investi-
gated for their possible associations with the death or
survival of patients were those suggested by
Fitzpatrick et al. [5] and Knight et al. [4] as risk factors
for AFE: caesarean section (yes or no), placenta previa
(yes or no), placenta abruptio (yes or no), multiple
pregnancy (yes or no), preeclampsia and/or hyperten-
sive disorders in pregnancy (yes or no), patient age
(35 years and <35 years), prostaglandin agonist use
(yes or no) and oxytocin use during labour for induc-
ing or augmenting labour (yes or no). We chose to
match for oxytocin use in labour because Fitzpatrick
et al. [5] did not specify which kind of induction
increases the risk of AFE.
Because AFE may present atypical behaviour
[3,7–9], it is possible that some authors suspected AFE
despite the fact that the case is not typical. Therefore,
we looked for typical cases of AFE based on the clin-
ical triad of signs [10]: cardiac arrest/cardiovascular col-
lapse, respiratory failure (dyspnea, cyanosis, severe
desaturation), coagulopathy (both overt and non-overt
disseminated intravascular coagulopathy). Those crite-
ria were very similar to the ones reported more
recently by Clark et al. [3], and were checked by care-
fully reading the case reports.
Based on the occurrence of signs and symptoms
of cardiovascular, pulmonary and coagulative failure
[10], authors have considered AFE cases as typical.
The use of laboratory or pathological information in
supporting AFE diagnosis, as reported in already-cited
meta-analysis [6], was used as additional criterion for
improving AFE diagnosis, allowing additional analysis
on sub-group of patients with both typical signs and
laboratory or pathological markers of amniotic
embolisation.
The information collected was initially used for car-
rying out the above-mentioned meta-analysis [6].
However, the data also allowed the current post-hoc
analyses. Therefore, we built three logistic regression
models, the first one on the whole data pool (typical
cases and atypical cases of AFE), the second one on
the typical cases of AFE and the third one on the sub-
group with typical AFE and some laboratory and/or
pathological confirmation of amniotic fluid embolisa-
tion. Significance was set at p< 0.05, and SPSS 16.0
(SPSS Inc., Chicago, IL) was used for calculations.
Results
After the systematic review, we retrieved 2374 referen-
ces. 2141 references were discarded either because
they were duplicates or because they were not case
reports, small series and letters (based on titles and
abstracts). Seven more references were added, as they
were incidentally found on Google Scholar during the
full text search. 20 references were discarded because
the full texts were unavailable. 66 references were dis-
carded during the phase of quality assessment of the
meta-analysis. 154 references involved 181 cases. We
discarded 3 cases due to insufficient information and
1 case because AFE was unlikely (177 case reports of
AFE available). Figure 1 shows the flow chart of the
systematic review.
Table 1 reports the descriptive statistics, disaggre-
gated for typical and atypical cases of AFE. Table 2
Figure 1. Flowchart of the systematic review (reproduced with
permission).
2 U. INDRACCOLO ET AL.
reports the unadjusted and adjusted odds ratios calcu-
lated after multivariable logistic regression analysis on
the whole data pool (177 cases). No variable seems
associated with death for AFE. Table 3 reports calcula-
tions on only typical cases of AFE (121 cases). Among
the independent variables, only oxytocin infusion
during labour increases the odds ratio of death in AFE
cases (odds ratio 2.890, 95% confidence interval
1.166–7.164, p¼ 0.022). Among patients with both
typical signs of AFE and some laboratory and/or
pathological markers of amniotic embolisation (47
cases), none of the independent variables associate
Table 1. Clinical characteristics of patients with typical and atypical amniotic fluid embolism.
Descriptive data
Variablesa Atypical cases (n¼ 56) Typical cases (n¼ 121)
Deaths 16 (28.6%) 37 (30.6%)
Age Mean: 31.4 ages Mean: 32.1 ages
SD: ±6.66 ages SD: ±6.22 ages
Missing: 1 (1.2%) Missing: 1 (0.8%)
35 years: 17 (30.9%) 35 years: 46 (38.3%)
Multiparity 24 (48%) 68 (59.6%)%
Missing: 6 (10.7%) Missing: 7 (5.8%)
Over 30 weeks 44 (81.4%) 104 (87.4%)
Missing: 2 (3.6%) Missing: 2 (1.7%)
Caesarean section 37 (66.1%) 82 (67.8%)
Vaginal delivery 10 (17.9%) 15 (12.4%)
Operative vaginal birth 4 (7.1%) 20 (16.5%)
Miscarriage or pregnancy interruption 3 (5.4%) 6 (5%)
Blund trauma 2 (3.6%) 2 (1.7%)
Multiple pregnancy 5 (8.9%) 10 (8.3%)
Previous cesarean 2 (3.6%) 15 (12.4%)
Placenta previa 2 (3.6%) 15 (12.4%)
Placenta percreta 0 5 (4.1%)
Placenta abruptio 4 (7.1%) 1 (0.8%)
Premature rupture of membranes or amniotomy 25 (44.6%) 37 (30.6%)
Preeclampsia or hypertensive disorders of pregnancy 2 (3.6%) 6 (5%)
Prostaglandin agonists use 9 (16.1%) 28 (23.1%)
Oxytocin infusion during labour 10 (17.9%) 27 (22.3%)
Spinal anaesthesia/analgesia 17 (30.4%) 49 (40.5%)
aThe rates of the above-mentioned variables were calculated on the total number of both atypical and typical AFE cases (descrip-
tive statistics).
Table 2. Multivariable logistic regression analysis on the
whole database (177 cases).
Unadjusted odds
ratio 95%
confidence intervals
Adjusted odds
ratio 95%
confidence intervals
p p
Placenta previa 1.347 1.323
0.432–4.198 0.439–3.988
0.608 0.619
Placenta abruptio 0.512 0.490
0.054–4.829 0.052–4.589
0.559 0.532
Age 35 yearsa 0.948 0.948
0.470–1.915 0.470–1.913
0.882 0.881
Cesarean section 0.815 0.845
0.391–1.697 0.417–1.712
0.584 0.639
Multiple pregnancy 0.984 0.984
0.284–3.409 0.284–3.409
0.980 0.980
Preeclampsia/hypertensive
disorders of pregnancy
0.430 0.406
0.050–3.727 0.048–3.457
0.430 0.410
Prostaglandin agonists 0.544 0.531
0.219–1.349 0.221–1.275
0.189 0.157
Oxytocin infusion during labour 2.012 1.830
0.909–4.454 0.861–3.892
0.085 0.116
aAs missing data are only two (1.1%), it was chosen to replace them with
mean.
Table 3. Multivariable logistic regression analysis on the typ-
ical cases of AFE (121 cases).
Unadjusted odds
ratio 95%
confidence intervals
Adjusted odds
ratio 95%
confidence intervals
p p
Placenta previa 1.080 1.077
0.306–3.810 0.314–3.690
0.905 0.906
Placenta abruptio 115.145 120.331
0–1 0–1
1.000 1.000
Age 35 yearsa 1.010 1.010
0.424–2.405 0.424–2.405
0.983 0.983
Cesarean section 1.216 1.229
0.484–3.058 0.499–3.025
0.678 0.654
Multiple pregnancy 0.575 0.577
0.106–3.132 0.112–2.959
0.522 0.509
Preeclampsia/hypertensive
disorders of pregnancy
0.848 0.841
0.084–8.528 0.084–8.414
0.889 0.883
Prostaglandin agonists 0.402 0.381
0.127–1.271 0.129–1.129
0.121 0.082
Oxytocin infusion during labour 2.521 2.890
0.971–6.545 1.166–7.164
0.057 0.022
aMissing case replaced with mean.
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with death, but the model overfits due to the paucity
of data (results not shown).
Discussion
This in-depth analysis of AFE cases seems to suggest
that, among the risk factors for AFE, the oxytocin use
in labour (induction or augmentation) could associate
with death if AFE onsets.
Caution in interpreting this result should be
applied, because a post-hoc analysis of a data pool
has some statistical flaws. The data pool is not the
sample randomly extracted from a defined population,
and the post-hoc analysis implies that cases were
selected with another aim [6].
Moreover, as we do not know how much oxytocin
was administered and how long the oxytocin adminis-
tration lasted in labouring women, a drug-related
effect cannot be speculated. Oxytocin during labour
was adminisetred to 17.9% of atypical and to 22.3% of
typical cases of AFE. Those rates were calculated on
the whole groups of patients with AFE, thereby
encompassing also patients not in labour (planned
cesareans, abortions/pregnancy interruptions, blunt
traumas: Table 1). Many population-based studies
report heterogeneous rates of oxytocin augmentation,
in relationship to obstetrical risk and obstetrical care
[11–14], with a trend to reduction from 34.9% to
23.1% – for example – in Norway [14]. Therefore, it is
difficult to compare rates of oxytocin administration
reported in the present study to the various policy of
oxytocin administration in labour worldwide.
Another point of caution in interpreting results is in
relationship to the amount of the true cases of AFE in
the series. The case definition of AFE remains challeng-
ing even after the publication of the article by Clark
et al. [3]. Therefore, it is impossible to ascertain which
case is not a true case of AFE. This kind of problem
causes uncertainty also in interpreting population-
based results among AFE cases. When stringent diag-
nostic criteria for AFE were used for finding sure AFE
cases, information from non-typical cases of AFE was
lost. We provided analysis on the whole data pool and
on the typical AFE cases, finding that oxytocin in
labour could be linked to fatality only in typical AFE
cases. This behaviour cannot be exhaustively
explained. A possible explanation could be that some
atypical AFE cases were not true AFE cases in this data
pool, leading to inconclusive results. However, Oi et al.
[15] found an “abundance ratio” among the factors
associated with fatality in AFE. Among these factors,
there are the typical symptoms of AFE and the level of
serum Syalil-Tn. The findings of Oi et al. [15] suggest
that AFE has varying degrees of severity, the more
severe is the disease (typical cases), the more severe is
the outcome. Theoretically, this degree of severity
should correlate with the amount of amniotic fluid
embolisation. To have an amniotic fluid embolisation,
two basic conditions are needed: the patency of ves-
sels across the uterine wall and cervix, and a gradient
of pressure from the amniotic cavity to the aforemen-
tioned vessels. Those conditions allow a flux of amni-
otic fluid, triggering AFE syndrome in predisposed
patients [16]. Some risk factors for AFE could increase
the amount of amniotic fluid embolisation [16],
thereby worsening the outcome of AFE. Among those,
the augmentation of labour with oxytocin could
increase intra-uterine pressure, thereby realising the
pressure gradient for amniotic fluid flow across the
uterine vessels.
Fitzpatrick et al. [5] did not find that misoprostol (a
prostaglandin agonist) increases the risk of AFE,
thereby leading one to imagine that AFE should be
related to other factors during labour induction.
Moreover, the national-based survey of McDonnell
et al. [17] highlights that some women with AFE and
induction have also had labour augmentation with
oxytocin; therefore, oxytocin augmentation of labour
and labour induction could be at least inter-correlated.
This inter-correlation could explain why induction is
related to AFE [5,18] despite the fact that misoprostol
use for induction is not related to AFE [5].
There are other side effects of oxytocin reported in
the literature that could worsen the prognosis of AFE:
during caesarean section, large doses of oxytocin cause
a reduction of systolic blood pressure [19] and myocar-
dial ischaemia [20]. It must be acknowledged that
doses of oxytocin during labour augmentation or
induction are lower than during caesarean section.
However, as cardiac depression is involved in AFE
pathophysiology [2], it should be proved if oxytocin
infusion during labour can worsen AFE prognosis by
acting on the cardiovascular system even at low doses.
The present study cannot determine if other condi-
tions could be associated with fatality in AFE because
some independent variables have a low rate of occur-
rence. We should consider that other clinical condi-
tions could increase the amount of amniotic fluid
embolisation. We hope that further case reports will
describe the clinical picture of AFE in greater detail,
allowing for a larger data pool. On the other hand,
national registries and data sources should be checked
to investigate the role of oxytocin infusion in labour in
AFE cases.
In conclusion, this study would suggest that oxyto-
cin use in labour associates with death if AFE onsets.
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Other presumptive factors linked with fatality in AFE
cases need a larger availability of data.
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